Trial Profile

A global phase 3 study of Telitacicept in primary Sjögren's disease

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 26 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telitacicept (Primary)
Indications Sjogren's syndrome
Focus Therapeutic Use

Most Recent Events

26 Dec 2025 New trial record
15 Dec 2025 According to a Vor Biopharma media release, the company has secured a financing of approximately $150 million by selling its shares. Vor Bio intends to use it for the initiation of a global Phase 3 clinical trial in primary Sjogren's disease.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com